Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.76 |
| ▸ | RAB9A | P51151 | 12/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.76 |
| ▸ | GFER | P55789 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.72 |
| ▸ | RELA | Q04206 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CASP3 | P42574 | 4/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | TP53 | P04637 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622897 | 1.00 | NPC1 (0.76) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL23748392 | 0.98 | NPC1 (0.73) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL2247126 | 0.91 | RAB9A (0.71) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL2251048 | 0.91 | RAB9A (0.71) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL2251225 | 0.90 | RAB9A (0.81) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL2244352 | 0.87 | NPC1 (0.76) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL29603993 | 0.86 | RAB9A (0.86) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL5654856 | 0.86 | RAB9A (0.86) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL29404722 | 0.86 | RAB9A (1.00) | NPC1RAB9ARXFP1GFERKDM4E | |
| SCHEMBL1852701 | 0.86 | RAB9A (1.00) | NPC1RAB9ARXFP1GFERKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | claimed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | claimed |
| EP-4247800-B1 | N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2024-11-13 | — | — | EP | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2022106589-A1 | N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| CN-114436971-A | Di (4- (benzoxazol-2-yl) phenyl) methylamine derivative and preparation method thereof | 陕西维世诺新材料有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210387953-A1 | BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2021-12-16 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| CN-1930121-A | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER PROD INC (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725524-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| WO-2005092845-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | NPC1 59/4885RAB9A 2271/4885RXFP1 2846/4885 |
| US-20230286930-A1 | N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2E1, CYP7A1 | NPC1 71/4885RAB9A 2085/4885RXFP1 2917/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885RAB9A 3748/4885RXFP1 1129/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | NPC1 74/4885RAB9A 2063/4885RXFP1 2788/4885 |
| US-20210387953-A1 | BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS | CLPX, SQSTM1, ATG7 | NPC1 807/4885RAB9A 77/4885RXFP1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.